Loading stock data…
MaxCyte, Inc. (MXCT)
$1.27-0.01 (-0.39%)
Market ClosedLast close Sep 8
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MaxCyte, Inc. in the Healthcare sector is trading at $1.27 with a market capitalization of $112M. Wall Street consensus targets $4.11 (4 analysts), implying a +222.2% move over the next 12 months. The stock is currently 32% below its 52-week high of $1.86, remaining 13.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +222.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.65M↑ | $7.30M↑ | $6.83M↓ | $8.51M↓ | $10.39M |
| Gross Profit | $8.08M↑ | $5.69M↑ | $5.23M↓ | $6.99M↓ | $8.89M |
| Operating Income | -$6.18M↑ | -$7.67M↑ | -$11.09M↑ | -$14.23M↓ | -$12.29M |
| Net Income | -$4.75M↑ | -$9.60M↑ | -$12.42M↓ | -$12.36M↓ | -$10.26M |
Peer Comparison
JNJUNHPFE
Fundamentals
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$112.48M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.66
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.30%
Volume
Today's trading volume
432,823
Recent News
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript
Revenue declined 15% year-over-year, but net losses narrowed significantly.
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...
MaxCyte Inc (MXCT) navigates a transitional quarter with a landmark Genentech deal and robust CASGEVY royalties, positioning for renewed growth in the second half of 2026.
MaxCyte, Inc. Q2 2026 Earnings Call Summary
Moby summary of MaxCyte, Inc.'s Q2 2026 earnings call
MaxCyte Q2 Earnings Call Highlights
MaxCyte (NASDAQ:MXCT) reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases affected results. Management said the quarter came in ahead of its expectation
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of +33.33% and +11.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?